Categories Earnings, Technology

iRobot posts upbeat Q3 earnings, but stock tumbles on weaker guidance

iRobot (NASDAQ: IRBT) reported a 9% growth in third-quarter revenues to $289.4 million, riding on strong international performance. The top-line surpassed the average analysts’ estimate of $259.38 million, which represented a year-over-year dip.

Even as revenues declined 7% in the US, this was offset by a 40% growth in Japan and 27% growth in EMEA.

irobot
Image courtesy: iRobot

On an adjusted basis net income for the third quarter rose to $1.50 per share, compared to $1.34 per share in the same quarter last year. Wall Street was expecting Q3 earnings of just $0.52 per share.

Trading of IRBT shares were halted just minutes ahead of the earnings announcement. When trading restarted, it fell almost 16%, on slashed revenue guidance for the holiday quarter. The stock has tumbled 28% since the beginning of this year.

irobot earnings Q3 2019

Outlook

The company narrowed its outlook on fiscal year 2019 revenue and operating income. It currently expects revenues for the full year in the range of $1.2 billion – $1.21 billion and operating income in the range of $75 million – $80 million.

Meanwhile, the guidance on full year EPS was narrowed to $2.60 – $2.80, from the prior estimate of $2.40 – $3.15.

READ: McDonald’s misses Q3 earnings target by 10 cents

CEO Colin Angle said, “Higher revenue in combination with favorable gross margins and disciplined spending enabled us to deliver strong quarterly operating income and EPS.”

The company had last quarter stated that it sees the recently implemented 25% tariffs to constrain its US market segment growth in the second half of the year.

Though the company is in the process of shifting production from China to Malaysia to offset some of the tariff headwinds, any material impact from these activities will take at least another two quarters to shape up.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top